# CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML

> **NCT04151706** · PHASE2 · COMPLETED · sponsor: **Robert Lowsky** · enrollment: 7 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndromes
- Acute Leukemia
- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** CD8+ Memory T Cell Infusion
- **DRUG:** Thiotepa
- **DRUG:** Fludarabine
- **RADIATION:** Hyperfractionated TBI
- **DRUG:** Busulfan
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT04151706
- **Lead sponsor:** Robert Lowsky
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-27
- **Primary completion:** 2023-09-08
- **Final completion:** 2023-09-08
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2024-10-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04151706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04151706, "CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04151706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*